Healthcare >> Analyst Interviews >> March 10, 2017
A Cautious Perspective on the Biotechnology Sector
Thomas Shrader, Ph.D. is a Managing Director in the health care sector, covering biotechnology, at Stifel, Nicolaus & Co., Inc. Dr. Shrader joined the firm in 2014 and is based out of the New York office. His past awards include The Wall Street Journal's Best on the Street survey award. Before joining Stifel, Nicolaus & Co., Inc., Dr. Shrader was the Director of Strategic Corporate Partnerships at Yale University and spent a decade as a Sellside Analyst, principally at BMO Capital Markets Corp. and its predecessors. Dr. Shrader has also been an Associate and Assistant Professor of biochemistry at the Albert Einstein College of Medicine — AECOM — where he directed a laboratory focused on infectious diseases drug target discovery. While at AECOM, he served as an external grant reviewer for the NIH, and was a member of the board of reviewers for a number of journals, including The Journal of Biological Chemistry, Trends in Microbiology and Genes & Development. Dr. Shrader was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology, earned a Ph.D. in molecular biophysics and biochemistry from Yale University and a Bachelor of Arts and Sciences in biophysics from Johns Hopkins University. Profile
TWST: What is your coverage?
Dr. Shrader: I cover a broad range of biotechnology across many different market caps. At some level I am a midcap analyst, but I do